Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

SAB Biotherapeutics (SABS) Equity Ratio (2020 - 2026)

SAB Biotherapeutics filings provide 7 years of Equity Ratio readings, the most recent being 0.91 for Q1 2026.

  • On a quarterly basis, Equity Ratio rose 62.86% to 0.91 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.91, a 62.86% increase, with the full-year FY2025 number at 0.88, up 49.19% from a year prior.
  • Equity Ratio hit 0.91 in Q1 2026 for SAB Biotherapeutics, up from 0.88 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.91 in Q1 2026 to a low of 0.4 in Q2 2025.
  • Median Equity Ratio over the past 5 years was 0.61 (2022), compared with a mean of 0.66.
  • Biggest five-year swings in Equity Ratio: soared 94.41% in 2022 and later tumbled 46.48% in 2025.
  • SAB Biotherapeutics' Equity Ratio stood at 0.61 in 2022, then rose by 11.88% to 0.68 in 2023, then fell by 13.92% to 0.59 in 2024, then soared by 49.19% to 0.88 in 2025, then grew by 4.33% to 0.91 in 2026.
  • The last three reported values for Equity Ratio were 0.91 (Q1 2026), 0.88 (Q4 2025), and 0.9 (Q3 2025) per Business Quant data.